Skip to main content
Healthcare

STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem 

STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem 

Feed excerpt — reported by STAT News

With the sales growth of the cardiomyopathy medication Amvuttra slowing, the company's stock price has tumbled.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.